The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability.

The unique region of structural protein VP1 of parvovirus B19 (erythrovirus B19) is important for eliciting neutralizing antibodies that are responsible for eliminating the virus from the peripheral blood and for inducing lifelong immunity. Neutralizing human MAbs bind a conformationally defined epitope spanning VP1 residues 30-42. The DNA sequence encoding the VP1-unique region was determined in parvovirus B19 isolated from peripheral blood and amniotic fluid of nine acutely infected pregnant women, five arthritis patients and two chronically infected children. The amino acid sequences of the VP1-unique region exhibited higher variability in comparison with other B19-specific proteins. To analyse the influence of amino acid variations on antibody binding and protein conformation, two variants of the VP1-unique region were selected and expressed in E. coli as intein-fusion proteins. The selected variants displayed a number of amino acid exchanges in the VP1-unique region and had mutations in the determined epitope and adjacent regions. After purification via affinity chromatography, the dissociation constants K(D) of VP1-specific human MAbs interacting with the variant antigens and a viral prototype of the VP1-unique region were determined with a quartz crystal microbalance biosensor. A value of 5.4 x 10(-8) M was determined for the prototype isolate pJB; the affinity constants for the variant VP1-unique regions were similar. Comparable values were obtained for interaction of antibodies with non-infectious VP1/VP2 capsids produced by recombinant baculovirus and with B19 virions from amniotic fluid. It is concluded that the conformation of the epitope is unaffected by mutations or the environment of the VP1-unique region in virus capsids.

[1]  Y. Konttinen,et al.  Integrity and full coding sequence of B19 virus DNA persisting in human synovial tissue. , 2000, The Journal of general virology.

[2]  A. Kroes,et al.  Human parvovirus B19: relevance in internal medicine. , 1999, The Netherlands journal of medicine.

[3]  S. Zolla-Pazner,et al.  Generation of Neutralizing Human Monoclonal Antibodies against Parvovirus B19 Proteins , 1999, Journal of Virology.

[4]  S. Drost,et al.  Characterization of immobilization methods for African swine fever virus protein and antibodies with a piezoelectric immunosensor. , 1998, Biosensors & bioelectronics.

[5]  K. Zakrzewska,et al.  Typing of European strains of parvovirus B19 by restriction endonuclease analyses and sequencing: identification of evolutionary lineages and evidence of recombination of markers from different lineages. , 1998, Virus research.

[6]  L. Anderson,et al.  Genetic diversity of human parvovirus B19: sequence analysis of the VP1/VP2 gene from multiple isolates. , 1996, The Journal of general virology.

[7]  S. Modrow,et al.  Sequence variability among different parvovirus B19 isolates. , 1996, The Journal of general virology.

[8]  H. Hasle,et al.  Chronic parvovirus infection mimicking myelodysplastic syndrome in a child with subclinical immunodeficiency. , 1994, The American journal of pediatric hematology/oncology.

[9]  K. Willwand,et al.  The major capsid protein VP2 of minute virus of mice (MVM) can form particles which bind to the 3'-terminal hairpin of MVM replicative-form DNA and package single-stranded viral progeny DNA , 1993, Journal of virology.

[10]  M. Anderson,et al.  Human parvovirus infection in homozygous sickle cell disease , 1993, The Lancet.

[11]  S. Kajigaya,et al.  Candidate recombinant vaccine for human B19 parvovirus. , 1993, The Journal of infectious diseases.

[12]  K. Saag,et al.  Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. , 1993, The Journal of infectious diseases.

[13]  S. Kajigaya,et al.  Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. , 1992, The Journal of clinical investigation.

[14]  A. Chott,et al.  Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection , 1992, British journal of haematology.

[15]  P. Woias,et al.  A quartz crystal biosensor for measurement in liquids. , 1992, Biosensors & bioelectronics.

[16]  S. Kajigaya,et al.  A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune response , 1991, Journal of virology.

[17]  H. Sato,et al.  Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies , 1991, Journal of virology.

[18]  J. Vlak,et al.  Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins , 1991, Journal of virology.

[19]  H. Sato,et al.  Identification of the region including the epitope for a monoclonal antibody which can neutralize human parvovirus B19 , 1991, Journal of virology.

[20]  S. Naides,et al.  Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. , 1990, Arthritis and rheumatism.

[21]  A. Woolf Human parvovirus B19 and arthritis. , 1990, Behring Institute Mitteilungen.

[22]  N. Young,et al.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection. , 1989, The Journal of clinical investigation.

[23]  D. W. Jenkins,et al.  Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. , 1989, The New England journal of medicine.

[24]  D. Melton,et al.  Structure and mapping of the DNA of human parvovirus B19. , 1987, The Journal of general virology.

[25]  N. Young,et al.  Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures , 1987, Journal of virology.

[26]  N. Young,et al.  Chronic bone marrow failure due to persistent B19 parvovirus infection. , 1987, The New England journal of medicine.

[27]  L. Anderson,et al.  Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments , 1986, Journal of virology.

[28]  P. Tattersall,et al.  Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis , 1986, Journal of virology.

[29]  D. Reid,et al.  HUMAN PARVOVIRUS-ASSOCIATED ARTHRITIS: A CLINICAL AND LABORATORY DESCRIPTION , 1985, The Lancet.

[30]  M. Anderson,et al.  Experimental parvoviral infection in humans. , 1985, The Journal of infectious diseases.

[31]  J. Clewley,et al.  INTRAUTERINE PARVOVIRUS INFECTION ASSOCIATED WITH HYDROPS FETALIS , 1984, The Lancet.

[32]  M. Anderson,et al.  HUMAN PARVOVIRUS, THE CAUSE OF ERYTHEMA INFECTIOSUM (FIFTH DISEASE)? , 1983, The Lancet.

[33]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Cant,et al.  PARVOVIRUS-LIKE PARTICLES IN HUMAN SERA , 1975, The Lancet.

[35]  A. Williamson,et al.  Molecular Immunology , 2020, Nature.